Peptic ulcer Medical Services in China

Peptic ulcer disease (PUD) refers to a break or sore in the mucosal lining of the stomach (gastric ulcer) or the first part of the small intestine (duodenal ulcer). These lesions result from an imbalance between aggressive factors—primarily gastric acid and pepsin—and the protective mechanisms of the mucosa, including mucus secretion, bicarbonate production, epithelial cell renewal, and adequate mucosal blood flow. The two dominant etiologies are infection with Helicobacter pylori (H. pylori), present in over 90% of duodenal ulcers and 70–80% of gastric ulcers, and chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs), which inhibit cyclooxygenase-1 (COX-1) and impair prostaglandin-mediated mucosal defense. Less common causes include Zollinger-Ellison syndrome, Crohn’s disease, malignancy (e.g., gastric adenocarcinoma or lymphoma), severe physiological stress (e.g., ICU patients with critical illness), and smoking—though smoking does not initiate ulcers, it impairs healing and increases recurrence risk. Epidemiologically, PUD affects approximately 5–10% of the global population at some point in life, with higher prevalence in older adults and in regions with limited access to H. pylori eradication therapy. In China, age-standardized incidence is estimated at 120–180 cases per 100,000 person-years, with duodenal ulcers more common than gastric ulcers (ratio ~3:1). Key modifiable risk factors include NSAID use (especially without gastroprotection), smoking, heavy alcohol consumption, untreated H. pylori infection, and prolonged psychological stress—though stress alone is not causative. Uncomplicated ulcers may cause intermittent epigastric pain (often burning or gnawing), bloating, early satiety, nausea, or hematemesis/melena if bleeding occurs. Complications—including gastrointestinal hemorrhage, perforation, gastric outlet obstruction, and malignant transformation (rare in duodenal ulcers but relevant in gastric ulcers)—significantly increase morbidity and mortality. Quality of life impact is substantial: chronic pain disrupts sleep, work productivity, dietary habits, and mental health; recurrent symptoms lead to anxiety about complications and frequent healthcare utilization; and long-term proton pump inhibitor (PPI) dependence may raise concerns about nutrient absorption (e.g., magnesium, vitamin B12) and bone health. Early diagnosis via upper endoscopy—gold standard for visualization, biopsy, and H. pylori testing—is essential to differentiate benign ulcers from malignancy and guide targeted therapy. With appropriate management, most ulcers heal within weeks and recurrence rates drop dramatically after successful H. pylori eradication.

Peptic ulcer disease (PUD) refers to mucosal defects in the stomach or duodenum extending through the muscularis mucosae, most commonly caused by Helicobacter pylori infection or nonsteroidal anti-inflammatory drug (NSAID) use. Management is stratified according to etiology, severity, complications (e.g., bleeding, perforation, obstruction), and patient comorbidities. Treatment goals include symptom relief, ulcer healing, eradication of underlying causative factors, prevention of recurrence, and mitigation of complications.

Conservative treatment forms the cornerstone of uncomplicated PUD management. It emphasizes lifestyle modification and risk factor mitigation. Patients are advised to discontinue NSAIDs whenever clinically feasible; if ongoing anti-inflammatory therapy is essential, co-prescription of a proton pump inhibitor (PPI) is mandatory. Smoking cessation is strongly recommended, as tobacco impairs mucosal blood flow, delays ulcer healing, and increases recurrence risk by up to 2-fold. While dietary restrictions are no longer evidence-based for routine ulcer healing, patients should avoid irritants that exacerbate symptoms—such as excessive caffeine, alcohol, and spicy foods—on an individualized basis. Stress reduction techniques may support adherence and symptom control but are not substitutes for pharmacologic therapy. Bed rest is unnecessary; however, activity modification during acute symptomatic phases may improve comfort.

Pharmacologic therapy is central to PUD management and follows evidence-based protocols. First-line treatment for H. pylori-positive ulcers is quadruple therapy: a high-dose PPI (e.g., esomeprazole 40 mg twice daily), bismuth subsalicylate 524 mg four times daily, tetracycline 500 mg four times daily, and metronidazole 500 mg three or four times daily—all administered for 10–14 days. In regions with low clarithromycin resistance (<15%), standard triple therapy (PPI + amoxicillin 1 g twice daily + clarithromycin 500 mg twice daily for 14 days) remains an option, though efficacy has declined globally. For NSAID-induced ulcers without H. pylori, high-dose PPI monotherapy (e.g., omeprazole 40 mg once daily or esomeprazole 40 mg once daily) for 4–8 weeks is standard. Healing rates exceed 90% at 8 weeks. Histamine-2 receptor antagonists (H2RAs) such as famotidine 40 mg twice daily are less effective than PPIs and reserved for mild cases or short-term symptom control. Sucralfate (1 g four times daily) may be used adjunctively in select patients intolerant to PPIs, though it lacks antimicrobial activity and does not prevent recurrence. Maintenance therapy is generally unnecessary after confirmed healing and eradication unless patients require long-term NSAIDs or have recurrent ulcers; in such cases, low-dose PPI prophylaxis is indicated.

Surgical intervention is now rare—reserved for life-threatening complications unresponsive to endoscopic or medical management. Indications include hemodynamically unstable upper gastrointestinal bleeding refractory to endoscopic hemostasis (e.g., visible vessel, spurting), free perforation with peritonitis, gastric outlet obstruction due to fibrotic stenosis unrelieved by endoscopic balloon dilation, or suspicion of malignancy in non-healing gastric ulcers. Procedures include laparoscopic or open oversewing of perforations, partial gastrectomy (Billroth I or II) for refractory bleeding or obstruction, and vagotomy (rarely performed today due to superior medical alternatives). Endoscopic interventions—including epinephrine injection, thermal coagulation, hemoclip placement, and over-the-scope clip (OTSC) deployment—are first-line for active bleeding and achieve definitive hemostasis in >90% of cases. Surgery carries higher morbidity (wound infection, anastomotic leak, dumping syndrome) and mortality (2–5% in elderly/comorbid patients) compared to endoscopic or medical approaches and is thus employed only when minimally invasive options fail.

Treatment in China offers distinct advantages rooted in integrated clinical infrastructure, national guideline harmonization, and technological adoption. The Chinese Society of Gastroenterology (CSG) publishes regularly updated, locally validated consensus guidelines incorporating regional antibiotic resistance patterns—particularly critical given China’s high metronidazole (>70%) and clarithromycin (>25%) resistance rates. This enables empiric regimens with >90% eradication success. Nationwide endoscopy networks ensure rapid access to high-definition white-light and image-enhanced endoscopy (e.g., narrow-band imaging, linked-color imaging), facilitating precise ulcer characterization, early malignancy detection, and real-time therapeutic intervention. Artificial intelligence–assisted endoscopic diagnosis systems—deployed across tier-1 hospitals—improve detection sensitivity for subtle lesions and post-eradication mucosal changes. Moreover, China’s centralized pharmaceutical procurement system ensures affordability and consistent availability of generic PPIs, bismuth compounds, and antibiotics, reducing treatment abandonment. Multidisciplinary ulcer clinics integrating gastroenterology, pathology, microbiology, and nutrition services optimize longitudinal care, particularly for complex or recurrent cases.

Recovery advice emphasizes structured follow-up and sustained behavioral adherence. All patients with gastric ulcers must undergo repeat endoscopy after 8–12 weeks to confirm healing and exclude malignancy—a mandatory step in China’s gastric cancer screening cascade. H. pylori eradication must be verified via urea breath test, stool antigen test, or biopsy-based histology at least 4 weeks after completing antibiotics and off PPIs for ≥2 weeks. Patients should avoid NSAIDs for at least 8 weeks post-healing; if reinitiation is unavoidable, concurrent PPI prophylaxis is non-negotiable. Alcohol intake should be limited to ≤14 units/week, and smoking cessation counseling with pharmacotherapy (varenicline or nicotine replacement) should be offered. Nutritional support includes small, frequent meals to reduce gastric distension and avoidance of late-night eating to minimize nocturnal acid breakthrough. Symptom diaries help identify triggers and assess treatment response. Long-term surveillance is advised for patients with chronic NSAID use, prior complicated ulcers, or familial gastric cancer history. With appropriate management, >95% of uncomplicated ulcers heal within 8 weeks, and recurrence rates fall below 10% at 1 year following successful H. pylori eradication and NSAID discontinuation.